Our laboratory studies and develops adoptive T cell (CAR T cell) therapies targeting solid tumors. The postdoctoral scientist will develop genetically engineered T-cell therapies starting from the molecular cloning phase of cell therapy development, and then advancing to preclinical in vitro work and clinically relevant mouse models. A strong background in molecular biology and immunology will allow the successful applicant to be creative within the lab, enhancing T cell function and tumor targeting for optimal patient translation and high-impact publication. The postdoctoral scientist will work under the co-mentorship of Leonid Cherkassky and Renier Brentjens. We have a rapidly advancing program engaged in cutting-edge preclinical science and are supported by a strong institutional commitment to translating cellular therapies to cancer patients.
PhD, MD, or MD/PhD within Immunology, Molecular Biology, Virology or a related field.
The candidate should have prior experience with commonly used laboratory methods and in vitro models to study the biology of immune cells and cancer. Expertise in cancer immunology or general experience in immunotherapy and molecular biology is required. Experience with mouse models of cancer and immunotherapy is recommended but not required. The candidate must be able to work independently, possess strong interpersonal skills, and have a proven track record of publication.
Interested candidates should provide a CV highlighting previous research work, a brief (<1 page) personal statement, and 3 references. Inquiries and applications should be sent to Leonid Cherkassky, MD at Leonid.Cherkassky@RoswellPark.org.
Applications may also be sent to Leonid Cherkassky, MD, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, CSC P-641, Buffalo NY 14203.